Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers

Molecular Pharmaceutics

Volumn 12, Issue 11, 2015, Pages 4085-4098

  Yi, Xiaoli ^a   Lian, Xianghong ^a   Dong, Jianxia ^a   Wan, Zhuoya ^a   Xia, Chunyu ^a   Song, Xu ^a   Fu, Yao ^a   Gong, Tao ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

combination chemotherapy; human serum albumin nanoparticles; paclitaxel; pirarubicin; synergistic effect; toxicity

Indexed keywords

HUMAN SERUM ALBUMIN; NANOCARRIER; PACLITAXEL; PIRARUBICIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; NANOPARTICLE; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL TOXICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SUSTAINED DRUG RELEASE; TANDEM MASS SPECTROMETRY; TUMOR VOLUME; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CELL CYCLE; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; GASTROINTESTINAL DISEASES; HUMAN; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, LEWIS LUNG; CELL CYCLE; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL DISEASES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; PACLITAXEL; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946554367     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00536     Document Type: Article

References (72)

1. Noh, I.; Kim, H.-O.; Choi, J.; Choi, Y.; Lee, D. K.; Huh, Y.-M.; Haam, S. Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer Biomaterials 2015, 53, 763-774 10.1016/j.biomaterials.2015.03.006
2. Hu, C.-M. J.; Zhang, L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer Biochem. Pharmacol. 2012, 83 (8) 1104-1111 10.1016/j.bcp.2012.01.008
3. Yan, Y.; Such, G. K.; Johnston, A. P.; Best, J. P.; Caruso, F. Engineering particles for therapeutic delivery: prospects and challenges ACS Nano 2012, 6 (5) 3663-3669 10.1021/nn3016162
4. Kang, L.; Gao, Z.; Huang, W.; Jin, M.; Wang, Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment Acta Pharm. Sin. B 2015, 5 (3) 169-175 10.1016/j.apsb.2015.03.001
5. Lv, S.; Tang, Z.; Li, M.; Lin, J.; Song, W.; Liu, H.; Huang, Y.; Zhang, Y.; Chen, X. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer Biomaterials 2014, 35 (23) 6118-6129 10.1016/j.biomaterials.2014.04.034
6. Liu, Y.; Fang, J.; Kim, Y.-J.; Wong, M. K.; Wang, P. Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity Mol. Pharmaceutics 2014, 11 (5) 1651-1661 10.1021/mp5000373
7. Lyman, G. H.; Green, S. J.; Ravdin, P. M.; Geyer, C. E., Jr; Russell, C. A.; Balcerzak, S. P.; Budd, G. T.; Martino, S. A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer Breast Cancer Res. Treat. 2004, 85 (2) 143-150 10.1023/B:BREA.0000025405.63953.f9
8. Cong, W.; Liu, Q.; Liang, Q.; Wang, Y.; Luo, G. Investigation on the interactions between pirarubicin and phospholipids Biophys. Chem. 2009, 143 (3) 154-160 10.1016/j.bpc.2009.05.005
9. Milross, C. G.; Mason, K. A.; Hunter, N. R.; Chung, W.-K.; Peters, L. J.; Milas, L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel J. Natl. Cancer Inst. 1996, 88 (18) 1308-1314 10.1093/jnci/88.18.1308
10. Kawano, K.; Takayama, K.; Nagai, T.; Maitani, Y. Preparation and pharmacokinetics of pirarubicin loaded dehydration-rehydration vesicles Int. J. Pharm. 2003, 252 (1) 73-79 10.1016/S0378-5173(02)00628-2
11. Chen, Y.; Zhang, W.; Huang, Y.; Gao, F.; Sha, X.; Fang, X. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor Int. J. Pharm. 2015, 488 (1) 44-58 10.1016/j.ijpharm.2015.04.048
12. Gustafson, D. L.; Merz, A. L.; Long, M. E. Pharmacokinetics of combined doxorubicin and paclitaxel in mice Cancer Lett. 2005, 220 (2) 161-169 10.1016/j.canlet.2004.09.007
13. Feng, T.; Tian, H.; Xu, C.; Lin, L.; Xie, Z.; Lam, M. H.-W.; Liang, H.; Chen, X. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment Eur. J. Pharm. Biopharm. 2014, 88 (3) 1086-1093 10.1016/j.ejpb.2014.09.012
14. McMeekin, D. S.; Sill, M. W.; Walker, J. L.; Moore, K. N.; Waggoner, S. E.; Thaker, P. H.; Rizack, T.; Hoffman, J. S.; Fracasso, P. M. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study Gynecol. Oncol. 2015, 138 (1) 36-40 10.1016/j.ygyno.2015.04.038
15. Cui, Y.; Xu, Q.; Chow, P. K.-H.; Wang, D.; Wang, C.-H. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment Biomaterials 2013, 34 (33) 8511-8520 10.1016/j.biomaterials.2013.07.075
16. Zhao, L.; Zhu, L.; Liu, F.; Liu, C.; Wang, Q.; Zhang, C.; Li, J.; Liu, J.; Qu, X.; Yang, Z. pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel Int. J. Pharm. 2011, 410 (1) 83-91 10.1016/j.ijpharm.2011.03.034
17. Hongo, A. et al. A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma Int. J. Clin. Oncol. 2010, 15, 476-483 10.1007/s10147-010-0099-9
18. Su, J.; Li, M.; Xu, H.; Hu, D. Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide Zhonghua yi xue za zhi 2011, 91, 1837-1839
19. Shimizu, T.; Iwasa, T.; Koike, S.; Nakamura, T.; Kanai, T.; Komatsu, D. Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer Gan to Kagaku Ryoho 2003, 30 (1) 105-109
20. Kleeberg, U.; Reichel, L.; Wander, H.-E.; Beyer, J.-H.; Essers, U.; Fiebig, H.; Salewski, E.; Greifenberg, B.; Edler, L. Phase II study of pirarubicin in metastatic breast cancer Onkologie 1990, 13 (3) 175-179 10.1159/000216753
21. Koh, E.; Ueda, Y.; Nakamura, T.; Kobayashi, A.; Katsuta, S.; Takahashi, H. Apoptosis in young rats with adriamycin-induced cardiomyopathy-comparison with pirarubicin, a new anthracycline derivative Pediatr. Res. 2002, 51 (2) 256-259 10.1203/00006450-200202000-00021
22. Farr, M.; Bacon, P. How and when should combination therapy be used? The role of an anchor drug Rheumatology 1995, 34 (suppl 2) 100-103 10.1093/rheumatology/XXXIV.suppl
23. Pérez-Herrero, E.; Fernández-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy Eur. J. Pharm. Biopharm. 2015, 93, 52-79 10.1016/j.ejpb.2015.03.018
24. Sun, R.; Liu, Y.; Li, S.-Y.; Shen, S.; Du, X.-J.; Xu, C.-F.; Cao, Z.-T.; Bao, Y.; Zhu, Y.-H.; Li, Y.-P. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells Biomaterials 2015, 37, 405-414 10.1016/j.biomaterials.2014.10.018
25. Zhang, J.; Miao, L.; Guo, S.; Zhang, Y.; Zhang, L.; Satterlee, A.; Kim, W. Y.; Huang, L. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model J. Controlled Release 2014, 182, 90-96 10.1016/j.jconrel.2014.03.016
26. Gill, K. K.; Kaddoumi, A.; Nazzal, S. Mixed micelles of PEG 2000-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: Enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines Eur. J. Pharm. Sci. 2012, 46 (1) 64-71 10.1016/j.ejps.2012.02.010
27. Baek, J.-S.; Cho, C.-W. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles Int. J. Pharm. 2015, 478 (2) 617-624 10.1016/j.ijpharm.2014.12.018
28. Shaikh, I. M.; Tan, K.-B.; Chaudhury, A.; Liu, Y.; Tan, B.-J.; Tan, B. M.; Chiu, G. N. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft J. Controlled Release 2013, 172 (3) 852-861 10.1016/j.jconrel.2013.10.025
29. Duong, H. H. P.; Yung, L.-Y. L. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment Int. J. Pharm. 2013, 454 (1) 486-495 10.1016/j.ijpharm.2013.06.017
30. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132 (3) 171-183 10.1016/j.jconrel.2008.05.010
31. Wan, X.; Zheng, X.; Pang, X.; Zhang, Z.; Jing, T.; Xu, W.; Zhang, Q. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer Int. J. Pharm. 2015, 484 (1) 16-28 10.1016/j.ijpharm.2015.02.037
32. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Albumin-based nanoparticles as potential controlled release drug delivery systems J. Controlled Release 2012, 157 (2) 168-182 10.1016/j.jconrel.2011.07.031
33. Yan, S.; Zhang, H.; Piao, J.; Chen, Y.; Gao, S.; Lu, C.; Niu, L.; Xia, Y.; Hu, Y.; Ji, R. Studies on the Preparation, Characterization and Intracellular Kinetics of JD27-loaded Human Serum Albumin Nanoparticles Procedia Eng. 2015, 102, 590-601 10.1016/j.proeng.2015.01.133
34. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery-New applications on the horizon J. Controlled Release 2012, 157 (1) 4-28 10.1016/j.jconrel.2011.09.069
35. Kratz, F. A clinical update of using albumin as a drug vehicle-A commentary J. Controlled Release 2014, 190, 331-336 10.1016/j.jconrel.2014.03.013
36. Ibrahim, N. K.; Samuels, B.; Page, R.; Doval, D.; Patel, K. M.; Rao, S.; Nair, M. K.; Bhar, P.; Desai, N.; Hortobagyi, G. N. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J. Clin. Oncol. 2005, 23 (25) 6019-6026 10.1200/JCO.2005.11.013
37. Megerdichian, C.; Olimpiadi, Y.; Hurvitz, S. A. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer Cancer Treat. Rev. 2014, 40 (5) 614-625 10.1016/j.ctrv.2014.02.001
38. Zhou, J.; Zhang, X.; Li, M.; Wu, W.; Sun, X.; Zhang, L.; Gong, T. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin Mol. Pharmaceutics 2013, 10 (10) 3832-3841 10.1021/mp400303w
39. Zhao, H.; Lu, H.; Gong, T.; Zhang, Z. Nanoemulsion loaded with lycobetaine-oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity Int. J. Nanomed. 2013, 8, 1959 10.2147/IJN.S43892
40. Hungerford, G.; Benesch, J.; Mano, J. F.; Reis, R. L. Effect of the labelling ratio on the photophysics of fluorescein isothiocyanate (FITC) conjugated to bovine serum albumin Photochem. Photobiol. Sci. 2007, 6 (2) 152-158 10.1039/B612870J
41. Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 2006, 58 (3) 621-681 10.1124/pr.58.3.10
42. Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70 (2) 440-446 10.1158/0008-5472.CAN-09-1947
43. Iversen, T.-G.; Skotland, T.; Sandvig, K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies Nano Today 2011, 6 (2) 176-185 10.1016/j.nantod.2011.02.003
44. Sahay, G.; Alakhova, D. Y.; Kabanov, A. V. Endocytosis of nanomedicines J. Controlled Release 2010, 145 (3) 182-195 10.1016/j.jconrel.2010.01.036
45. Bareford, L. M.; Swaan, P. W. Endocytic mechanisms for targeted drug delivery Adv. Drug Delivery Rev. 2007, 59 (8) 748-758 10.1016/j.addr.2007.06.008
46. Lian, X.; Dong, J.; Zhang, J.; Teng, Y.; Lin, Q.; Fu, Y.; Gong, T. Soluplus® based 9-nitrocamptothecin solid dispersion for peroral administration: Preparation, characterization, in vitro and in vivo evaluation Int. J. Pharm. 2014, 477 (1) 399-407 10.1016/j.ijpharm.2014.10.055
47. Kessel, D. Properties of cremophor EL micelles probed by fluorescence[J] Photochem. Photobiol. 1992, 56 (4) 447-451 10.1111/j.1751-1097.1992.tb02187.x
48. Scholzen, T.; Gerdes, J. The Ki-67 protein: from the known and the unknown J. Cell. Physiol. 2000, 182, 311-22 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
49. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary ligand binding properties of human serum albumin IUBMB Life 2005, 57 (12) 787-796 10.1080/15216540500404093
50. Fu, Q.; Sun, J.; Zhang, W.; Sui, X.; Yan, Z.; He, Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery Recent Pat. Anti-Cancer Drug Discovery 2009, 4 (3) 262-272 10.2174/157489209789206869
51. Gao, H.; Cao, S.; Chen, C.; Cao, S.; Yang, Z.; Pang, Z.; Xi, Z.; Pan, S.; Zhang, Q.; Jiang, X. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer Nanomedicine 2013, 8 (9) 1429-1442 10.2217/nnm.12.180
52. Nakamura, H.; Etrych, T.; Chytil, P.; Ohkubo, M.; Fang, J.; Ulbrich, K.; Maeda, H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl) methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage J. Controlled Release 2014, 174, 81-87 10.1016/j.jconrel.2013.11.011
53. Nakamura, H.; Koziolová, E.; Etrych, T.; Chytil, P.; Fang, J.; Ulbrich, K.; Maeda, H. Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice Eur. J. Pharm. Biopharm. 2015, 90, 90-96 10.1016/j.ejpb.2014.10.007
54. Nagai, K.; Nagasawa, K.; Ishimoto, A.; Fujimoto, S. Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells Cancer Chemother. Pharmacol. 2003, 51 (6) 512-518 10.1007/s00280-003-0569-0
55. Li, N.; Li, N.; Yi, Q.; Luo, K.; Guo, C.; Pan, D.; Gu, Z. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent Biomaterials 2014, 35 (35) 9529-9545 10.1016/j.biomaterials.2014.07.059
56. Mayer, L. D.; Harasym, T. O.; Tardi, P. G.; Harasym, N. L.; Shew, C. R.; Johnstone, S. A.; Ramsay, E. C.; Bally, M. B.; Janoff, A. S. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 2006, 5 (7) 1854-1863 10.1158/1535-7163.MCT-06-0118
57. Wang, H.; Zhao, Y.; Wu, Y.; Hu, Y.-l.; Nan, K.; Nie, G.; Chen, H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles Biomaterials 2011, 32 (32) 8281-8290 10.1016/j.biomaterials.2011.07.032
58. Sparreboom, A.; Scripture, C. D.; Trieu, V.; Williams, P. J.; De, T.; Yang, A.; Beals, B.; Figg, W. D.; Hawkins, M.; Desai, N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 2005, 11 (11) 4136-4143 10.1158/1078-0432.CCR-04-2291
59. Gardner, E. R.; Dahut, W. L.; Scripture, C. D.; Jones, J.; Aragon-Ching, J. B.; Desai, N.; Hawkins, M. J.; Sparreboom, A.; Figg, W. D. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel Clin. Cancer Res. 2008, 14 (13) 4200-4205 10.1158/1078-0432.CCR-07-4592
60. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin. Cancer Res. 2006, 12 (4) 1317-1324 10.1158/1078-0432.CCR-05-1634
61. Hawkins, M. J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical medicine Adv. Drug Delivery Rev. 2008, 60 (8) 876-885 10.1016/j.addr.2007.08.044
62. Kumar, G.; Walle, U.; Bhalla, K.; Walle, T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein Res. Commun. Chem. Pathol. Pharmacol 1993, 80 (3) 337-344
63. He, S.; Cui, Z.; Mei, D.; Zhang, H.; Wang, X.; Dai, W.; Zhang, Q. A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo AAPS PharmSciTech 2012, 13 (3) 846-852 10.1208/s12249-012-9809-0
64. Robert, J.; Monnier, A.; Poutignat, N.; Herait, P. A Pharmacokinetic and Pharmacodynamic Study of the New Anthracycline Pirarubicin in Breast-Cancer Patients Cancer Chemother. Pharmacol. 1991, 29 (1) 75-79 10.1007/BF00686340
65. Fetterly, G. J.; Straubinger, R. M. Pharmacokinetics of paclitaxel-containing liposomes in rats AAPS PharmSci 2003, 5 (4) 90-100 10.1208/ps050432
66. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer Nature 2004, 432 (7015) 316-323 10.1038/nature03097
67. Spielmann, M.; Kerbrat, P.; Delozier, T.; Fumoleau, P.; Monnier, A.; Chevallier, B.; Bastit, P.; Namer, M.; Cattan, A.; Lucas, P. Pirarubicin in advanced breast cancer: a French cooperative phase II study Eur. J. Cancer Clin. Oncol. 1990, 26 (7) 821-823 10.1016/0277-5379(90)90161-L
68. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 2005, 23 (31) 7794-7803 10.1200/JCO.2005.04.937
69. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (8) 4607-4612 10.1073/pnas.95.8.4607
70. Vogel, S. M.; Minshall, R. D.; Pilipović, M.; Tiruppathi, C.; Malik, A. B. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein Am. J. Physiol Lung Cell Mol. Physiol 2001, 281 (6) L1512-L1522
71. He, X.; Xiang, N.; Zhang, J.; Zhou, J.; Fu, Y.; Gong, T.; Zhang, Z. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity Int. J. Pharm. 2015, 487 (1) 250-259 10.1016/j.ijpharm.2015.04.047
72. Framson, P. E.; Sage, E. H. SPARC and tumor growth: where the seed meets the soil? J. Cell. Biochem. 2004, 92 (4) 679-690 10.1002/jcb.20091